Paeoniflorin

Specifications

Purity

≥98% (HPLC)

Appearance

White to off-white powder

Identity

1H-NMR

Properties

Solvents

DMSO, DMF, ethanol (all 20mg/ml), water (10mg/ml).

Shipping

AMBIENT

Short Term Storage

RT

Long Term Storage

RT

Handling Advice

Protect from light and moisture.

Use / Stability

Stable for at least 2 years after receipt when stored at RT.

Transportation

Not dangerous goods

Description

Paeoniflorin has diverse cellular actions, including modulating NMDA and TRPV1 receptors. It is reported to inhibit testosterone synthesis and stimulate aromatase activity. It also reduces inflammatory signaling by inhibiting p38 MAP kinase and blocks pancreatic cancer cell apoptosis by suppressing MMP-2/9 and ERK signaling. It has been described as an adenosine A1 receptor activator with neuroprotective and antidepressant effects, as well as hypoglycemic activity. It can activate adenosine A-1 receptors to increase the translocations of PKC and GLUT4, two major signals for glucose uptake, from cytosol to membrane of the white adipocytes in rats. Recently it also was described as a liver X receptor (LXR) agonist, that can act as a ligand-activated transcription factor to exhibit antihyperlipidemic and neuroprotective effects. In addition, this potential anticancer agent, has ben described as a EP2 receptor agonists, a heat-shock protein (HSP)-inducing compound, by activation of HSF1, or by interacting with NOTCH1 or mTOR/HIF-1 signaling pathways.

Smiles

O[C@]12O[C@@]3([H])O[C@](C2)(C)[C@@]4([C@@]3(COC(C5=CC=CC=C5)=O)[C@@]1([H])C4)O[C@@H]([C@@H]([C@H]6O)O)O[C@H](CO)[C@H]6O

InChi Key

YKRGDOXKVOZESV-WRJNSLSBSA-N

References

(1) J. Yamahara, et al., J. Pharmacobiodyn. 5, 921 (1982) , (2) T. Takeuchi, et al., Amer. J. Chin. Med. 19, 73 (1991) , (3) F.L. Hsu, et al., Planta Med. 63, 323 (1997) , (4) C.W. Lai, et al., Life Sci. 62, 1591 (1998) , (5) H.O. Yang, et al., Fitoterapia 75, 45 (2004) , (6) D. Yan, et al., Cell Stress Chaperones 9, 378 (2004) , (7) D.Z. Liu, et al., Br. J. Pharmacol. 146, 604 (2005) , (8) H.Q. Liu, et al., Br. J. Pharmacol. 148, 314 (2006) , (9) J.Y. Hung, et al., Clin. Exp. Pharmacol. Physiol. 35, 141 (2008) , (10) H. Wu, et al., Biomed. Pharmacother. 62, 659 (2008) , (11) J. Fu, et al., Comp. Med. 59, 557 (2009) , (12) J. Huang, et al., Int. Immunopharmacol. 10, 1279 (2010) , (13) Q.Q. Mao, et al., Phytother. Res. 25, 681 (2011) , (14) S. Hu, et al., Anticancer Drugs 24, 140 (2013) , (15) R.B. Guo, et al., PLoS One 7, e49701 (2012) , (16) H.R. Lin, J. Asian Nat. Prod. Res. 15, 35 (2013) , (17) F.M. Qiu, et al., Neurosci. Lett. 541, 209 (2013) , (18) W. Li, et al., Mol. Med. Rep. 12, 2735 (2015) , (19) F. Han, et al., Cell Biosci. 6, 37 (2016) , (20) S. Wang & W. Liu, Mol. Med. Rep. 14, 2143 (2016) , (21) R. Lu, et al., Biomed. Pharmacother. 96, 137 (2017) , (22) J. Zhang, et al., Mol. Med. Rep. 17, 1321 (2018) , (23) H. Wang, et al., J. Cell Physiol. (Epub ahead of print) (2018) , (24) L.B. Jin, et al., Mol. Med. Rep. 17, 5095 (2018)